Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as LY3838915
LOXO-260 · 1 trial · 2 indications
DLT rate
| Arm | Type | Description |
|---|---|---|
| Phase 1A: LOXO-260 Dose Escalation | EXPERIMENTAL | LOXO-260 administered orally |
| Phase 1B: LOXO-260 Dose Expansion | EXPERIMENTAL | LOXO-260 administered orally |
| Name | Type | Description |
|---|---|---|
| LOXO-260 | DRUG | Oral |
Inclusion Criteria: * Must be ≥ 18 years of age at the time of signing the informed consent (Phase 1a and Phase 1b). Patients 12 years and older may be enrolled in Phase 1b for countries and sites where approved. * Must have evidence of a previously documented RET fusion (solid tumors) or RET mutat...
LOXO-260 is an investigational small molecule being studied in cancer patients, including those with non-small-cell lung carcinoma and thyroid neoplasms. It is designed for patients whose tumors have a change in the RET gene and whose disease has not responded to prior treatment. It is not approved for any use.
LOXO-260 is being developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. The compound is part of Lilly's oncology pipeline and is being studied in a biomarker-selected patient population with RET-altered tumors.
LOXO-260 is in Phase 1 clinical development. It is an investigational agent and has not been approved by the FDA or any other regulatory authority. The Phase 1 study has completed enrollment of 70 patients across the United States and France.
LOXO-260 has been evaluated in the Phase 1 trial NCT05241834, titled A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment. The trial enrolled 70 patients, included sites in the United States and France, and is now completed.
LOXO-260 is a small molecule directed at RET, a gene that can carry alterations in certain cancers. The Phase 1 trial NCT05241834 selected patients whose tumors had a change in the RET gene and who had not responded to prior treatment, including those with non-small-cell lung carcinoma and thyroid neoplasms.
No. LOXO-260 is an investigational drug in Phase 1 clinical development and is not FDA approved. Its only listed trial, NCT05241834, has completed with 70 patients enrolled. Approval status would only change if the developer reports regulatory action, which has not occurred.